Induction of ErbB-3 expression by alpha6beta4 integrin contributes to tamoxifen resistance in ERbeta1-negative breast carcinomas.
<h4>Background</h4>Tamoxifen is still the most widely used drug in hormone therapy for the treatment of breast cancer. Its benefits in adjuvant treatment are well documented in controlled and randomized clinical studies, which have demonstrated an increase in disease-free intervals of pa...
Guardado en:
Autores principales: | Valentina Folgiero, Paolo Avetrani, Giulia Bon, Selene E Di Carlo, Alessandra Fabi, Cecilia Nisticò, Patrizia Vici, Elisa Melucci, Simonetta Buglioni, Letizia Perracchio, Isabella Sperduti, Laura Rosanò, Ada Sacchi, Marcella Mottolese, Rita Falcioni |
---|---|
Formato: | article |
Lenguaje: | EN |
Publicado: |
Public Library of Science (PLoS)
2008
|
Materias: | |
Acceso en línea: | https://doaj.org/article/66d59f94593e4c78821476da0f2174ef |
Etiquetas: |
Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
|
Ejemplares similares
-
ErbB1 and ErbB3 co-over expression as a prognostic factor in gastric cancer
por: Moghbeli,Meysam, et al.
Publicado: (2019) -
Betacellulin-induced beta cell proliferation and regeneration is mediated by activation of ErbB-1 and ErbB-2 receptors.
por: Yoon Sin Oh, et al.
Publicado: (2011) -
Hyperleptinemia in obese state renders luminal breast cancers refractory to tamoxifen by coordinating a crosstalk between Med1, miR205 and ErbB
por: Arumugam Nagalingam, et al.
Publicado: (2021) -
Increased NRG1-ErbB4 signaling in human symptomatic epilepsy
por: Jun-Ming Zhu, et al.
Publicado: (2017) -
Anti-tubulin drugs conjugated to anti-ErbB antibodies selectively radiosensitize
por: Stephen R. Adams, et al.
Publicado: (2016)